Systematic review of 116 trials (10 RCTs, n=3,081, meta-analysed) in advanced NSCLC after prior immunotherapy: PD-(L)1 rechallenge modestly improved OS (HR 0.91) and PFS (HR 0.89) vs controls, with no ORR gain and no benefit in primary resistance.
Meta-analysisn = 3,081
Marinelli et al. PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes